Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Fennec Pharmaceuticals reported a 73% year-over-year increase in Q1 2026 net revenues to $15.1 million driven by increased demand for PEDMARK®, an FDA-approved drug to reduce cisplatin-induced ototoxicity in pediatric cancer patients. The company initiated a new clinical study, expanded its sales force, and secured multiple abstract acceptances for…